KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata, Shogo Nomura, Yosuke Kawashima, Eiji Iwama, Toshihide Yokoyama, Yasutaka Watanabe, Hiroshi Tanaka, Yutaka Fujiwara, Yoshitaka Zenke, Koichi Azuma, Hirokazu Taniguchi, Ryo Toyozawa, Yukio Hosomi, Haruyasu Murakami, Satoshi Hara, Akihiro Bessho, Nobuyuki Yamamoto, Yuichiro Ohe

Clin Cancer Res 31(12) 2317-2326

PMID40162917
PMCIDPMC12163600
DOI10.1158/1078-0432.CCR-24-3532
发表日期2025-03-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSqNSCLC) harboring EGFR mutation. PATIENTS AND METHODS: This was an open-label, multicenter, randomized phase III study. Patients with chemotherapy-naïve advanced or recurrent NSqNSCLC harboring EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were randomly assigned (1:1) to EGFR-TKI monotherapy or the EGFR TKI plus intercalated chemotherapy group. The primary endpoint was OS, and the secondary endpoints included progression-free survival (PFS). RESULTS: From December 2015 to October 2020, 501 patients were randomized. The EGFR TKI was changed from gefitinib to osimertinib in October 2018 (gefitinib cohort: n = 308 and osimertinib cohort: n = 193). There was no survival advantage in the EGFR TKI plus intercalated chemotherapy group; the median survival time of both groups was 48.0 months (HR, 0.985; 91.4% confidence interval, 0.796-1.219; one-sided P = 0.4496). The median PFS time was 12.0 months in the EGFR-TKI monotherapy group and 18.0 months in the EGFR TKI plus intercalated chemotherapy group (HR, 0.762; 95% confidence interval, 0.628-0.925; one-sided P = 0.003). The OS and PFS trends in both gefitinib and osimertinib cohorts were identical to those in the entire population. CONCLUSIONS: The intercalation of cisplatin plus pemetrexed after the response to EGFR TKI improved PFS but not OS compared with EGFR TKI monotherapy as the first-line treatment for patients with advanced NSqNSCLC harboring EGFR mutation.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2.

Kaplan–Meier analysis of OS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year survival rates were 92.8%, 80.4%, 63.5%, 49.6%, and 36.9% in the control group and 94.4%, 81.7%, 69.9%, 49.9%, and 35.3% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year survival rates were 91.5%, 78.4%, 59.5%, 46.3%, and 34.4% in the control group and 92.2%, 77.7%, 66.4%, 46.5%, and 32.9% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year survival rates were 94.8%, 83.4%, and 69.8% in the control group and 97.9%, 88.3%, and 76.0% in the experimental group, respectively. D, Subgroup analysis of OS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; NE; not estimable; PS, performance status.

A

OS

Figure 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Figure 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

Figure 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.CONSORT diagram. Flowchart of patient disposition throughout the study, including randomization, eligibility, treatment, and follow-up.
非 KM Figure
Figure 3.Kaplan–Meier analysis of PFS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 49.2%, 26.0%, 18.0%, 12.9%, and 7.8% in the control group and 67.0%, 39.8%, 24.1%, 11.9%, and 9.5% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 37.3%, 13.7%, 8.5%, 6.5%, and 4.0% in the control group and 59.5%, 32.7%, 15.7%, 7.2%, and 5.7% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year PFS rates were 68.0%, 45.3%, and 32.2% in the control group and 79.0%, 51.4%, and 39.6% in the experimental group, respectively. D, Subgroup analysis of PFS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; PS, performance status.
非 KM Figure